HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Karyopharm Therapeutics, maintaining a $7 price target.
November 01, 2024 | 9:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Karyopharm Therapeutics, maintaining a $7 price target.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in KPTI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100